Genentech And Ipsen Agree To Develop Sustained-Release Formulations Of Recombinant Human Growth Hormone

23-Mar-2005

Genentech, Inc. and Ipsen announced the recent execution of a collaborative research and development (R&D) agreement to develop sustained-release formulations of Genentech's recombinant human growth hormone [somatropin (rDNA origin)].

This R&D collaboration is in addition to and supplements a previous agreement signed in 2002 whereby Ipsen gained exclusive rights to market NutropinAq(TM) Pen throughout Europe and the rest of the world, excluding North America and Japan. Nutropin AQ Pen® for use with the Nutropin AQ Pen® cartridge was cleared for marketing by the U.S. Food and Drug Administration in April 2002 and obtained marketing authorization under the trade name NutropinAq Pen from the European Medicines Agency in March 2004. Ipsen has already launched NutropinAq Pen in 12 European countries.

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...